Recent Updates
Recently added Catalysts

agilon health, inc.

AGLFDA catalysts, PDUFA dates & pipeline intelligence
$90.24
▲ +0.74 · +0.83%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full AGL financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $7.4852W HIGH $133.04
Volume
266.33 K
Value Traded
23.72 M
Short % Float
7.22%
Days to Cover
4.7
-21.98%Week
-0.82%1 Month
-6.56%3 Month
+4.46%6 Month
+590.96%1 Year
-84.41%5 Year

Cash Data

Unlock AGL cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.52 B
EPS (TTM)
-5.22
P/E Ratio
-
Ent. Value
1.31 B
Total Shares
16.80 M
Float Shares
11.72 M
Insiders
30.23%
Institutions
72.96%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every AGL catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

AGL Catalyst Timeline

Dated clinical, regulatory and corporate events for agilon health, inc.

Unlock the full AGL catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How AGL actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all AGL historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

agilon health, inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every AGL program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every AGL trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock AGL insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Schwaneke Jeffrey A.Officer (Chief Financial Officer)Disposition -2,311 138,031 held$111.74 07/01/2026
Unlock the full AGL insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Avidity Partners 0.3 % 1.32 M 305.10 K
Unlock every fund holding AGL
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in AGL
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see AGL ownership
Insider and institutional ownership, quarter by quarter.

AGL Short Interest

Shares sold short, counted twice a month.

7.22%
Short % of Float
of tradable shares sold short
846.7K
Shares Sold Short
-5.8% vs prior count
4.7 Moderate
Days to Cover
trading days of normal volume to buy every short share back
179.7K
Avg Daily Volume
the average used for days to cover
Unlock AGL short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-12-18
Unlock AGL option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live AGL option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock AGL options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How AGL ranks across every disease it competes in

Competitive Position is a premium feature
See how AGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

AGL News

-AGL
Nov 5, 2026
AGLConferences/Events
▲ +18.2%on this news

agilon health to Host Virtual Investor Event “Driving Performance At Scale: The agilon Framework” on November 17, 2026

Agilon Health announced a virtual investor event scheduled for November 17, 2026. Key executives will discuss the company's clinical strategy, technology platform, and quality initiatives. The event aims to showcase the value delivered to physician partners and patients through the Total Care Model, followed by a live Q&A session.

Read more →
-AGL
Nov 4, 2026
AGLGeneral
▲ +18.2%on this newsshared move

agilon health Reports Third Quarter 2026 Results

Agilon Health reported a 6% revenue increase to $1.52 billion for Q3 2026. The company also achieved a net income of $35 million, a significant turnaround from a loss of $110 million in the same quarter last year. Adjusted EBITDA improved to $64 million, reflecting operational progress and effective payor contracting.

Read more →
-AGL
Oct 5, 2026
AGLConferences/Events

agilon health Sets Date to Report Third Quarter 2026 Financial Results

Agilon Health, Inc. announced it will release its financial results for the third quarter of 2026 after market close on November 4, 2026. A conference call will follow at 4:30 p.m. ET to discuss these results. The call will be accessible via phone and webcast, with a replay available afterward.

Read more →
-AGL
Sep 30, 2026
AGLGeneral

agilon health and The Jackson Clinic Advance Their Partnership Through Senior Health Connect ACO

Agilon Health has expanded its partnership with The Jackson Clinic by integrating it into its Senior Health Connect Accountable Care Organizations (ACOs). This collaboration is expected to enhance healthcare delivery by leveraging The Jackson Clinic's extensive network of over 130 providers across various specialties. The partnership aims to empower physicians and improve patient outcomes in the community.

Read more →
-AGL
Sep 23, 2026
AGLGeneral

agilon health and Springfield Clinic Broaden Partnership Through Senior Health Connect ACO

Agilon Health has announced an expansion of its partnership with Springfield Clinic, which will now join its Senior Health Connect Accountable Care Organizations (ACOs). This collaboration aims to enhance healthcare delivery and improve patient outcomes in the community. Springfield Clinic, with over 650 physicians, is well-positioned to contribute to this initiative.

Read more →
-AGL
Sep 10, 2026
AGLGeneral

agilon health and Family Practice Center Expand Relationship Through Senior Health Connect ACO

Agilon Health has expanded its partnership with Family Practice Center in Pennsylvania, integrating the latter into its Senior Health Connect Accountable Care Organizations. This collaboration aims to enhance healthcare services for seniors, leveraging the strengths of Family Practice Center, which serves over 200,000 patients. The move reflects agilon's commitment to empowering physicians and improving community health.

Read more →
-AGL
Aug 27, 2026
AGLConferences/Events

agilon health Announces Revised Presentation Time at the 2026 Jefferies Healthcare Services and Technology Conference

Agilon Health announced a revised presentation time for its management team at the 2026 Jefferies Healthcare Services and Technology Conference. The fireside chat is scheduled for 4:00 PM ET on September 14, 2026. Investors can listen to the presentation via a webcast on the company's investor relations website.

Read more →
-AGL
Aug 20, 2026
AGLConferences/Events

agilon health to Participate in Upcoming Conferences

Agilon Health, Inc. (NYSE: AGL) announced its participation in several upcoming conferences, including the Wells Fargo 21st Annual Healthcare Conference and the Jefferies Healthcare Services and Technology Conference. The management team will engage in a fireside chat, with webcasts available for some events. Agilon aims to empower physicians and enhance healthcare delivery.

Read more →
-AGL
Aug 5, 2026
AGLGeneral
▼ -19.5%on this news

agilon health Reports Second Quarter 2026 Results

Agilon Health, Inc. reported strong second quarter results for 2026, surpassing expectations. The company also raised its full-year guidance for total revenues, medical margin, and Adjusted EBITDA. This performance highlights the effectiveness of Agilon's strategic initiatives and boosts confidence in future growth.

Read more →
-AGL
Jul 10, 2026
AGLGeneral

agilon health Reports ACO REACH Model Results for 2024 Performance Year

Agilon Health reported significant financial results for its ACOs under the ACO REACH model for the 2024 performance year. The company achieved $229 million in gross savings, translating to a 13.6% savings rate, with $54 million benefiting the Medicare Trust Fund. This performance highlights the effectiveness of agilon's approach in managing healthcare costs.

Read more →
-AGL
Jul 7, 2026
AGLGeneral

agilon health Sets Date to Report Second Quarter 2026 Financial Results

Agilon Health has announced the date for its second quarter 2026 financial results report. The specific details regarding the report's content or any anticipated highlights were not provided in the announcement.

Read more →
-AGL
May 6, 2026
AGLGeneral

agilon health Reports First Quarter 2026 Results

Agilon Health has reported its financial results for the first quarter of 2026. The article provides limited details regarding the performance metrics or any significant developments during this period. Further insights into the company's operations or future outlook are not provided.

Read more →
-AGL
May 6, 2026
AGLGeneral

agilon health Reports First Quarter 2026 Results Raises Full-Year 2026 Total Revenues, Medical Margin and Adjusted EBITDA Guidance

Agilon Health reported its first-quarter results for 2026, showcasing a 162% increase in Adjusted EBITDA and positive short-term guidance for total revenues and medical margins. The company saw some challenges, including an 11% drop in total members, impacted by strategic market exits. Leadership changes, including the appointment of a new CEO, signal a focus on operational enhancement. Despite a decrease in year-over-year revenue, the firm expressed confidence in its long-term growth trajectory.

Read more →
-AGL
Apr 27, 2026
AGLGeneral

agilon health Appoints Tim O’Rourke as Chief Executive Officer

Agilon Health has appointed Tim O’Rourke as the new Chief Executive Officer. This leadership change is expected to impact the company's strategic direction. Further details about O'Rourke's background and plans for the company have not been disclosed in the article.

Read more →
-AGL
Apr 27, 2026
AGLGeneral

agilon health Appoints Tim O'Rourke as Chief Executive Officer Healthcare industry veteran with more than 25 years of payor, provider and value-based care leadership to lead agilon's next chapter

Agilon Health has announced the appointment of Tim O'Rourke as its new Chief Executive Officer, effective May 7, 2026, following a comprehensive search. O'Rourke succeeds Ronald A. Williams, who will remain as Chairman of the Board. With over 25 years in healthcare leadership, O'Rourke aims to build on agilon's recent operational and financial improvements, focusing on delivering value-based care. He expresses confidence in supporting the company's physician partners to achieve sustainable health care outcomes.

Read more →
-AGL
Apr 6, 2026
AGLGeneral
▲ +30%on this news· ran to +85% by day 3

agilon health Sets Date to Report First Quarter 2026 Financial Results

Agilon Health has announced the date for reporting its financial results for the first quarter of 2026. The specific date has not been detailed in the article. This announcement is part of the company's regular financial reporting schedule.

Read more →
-AGL
Mar 18, 2026
AGLGeneral

agilon health Announces Reverse Stock Split

Agilon Health, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-25, effective March 30, 2026. This decision follows the approval by stockholders at a special meeting and is aimed at increasing the stock price above $1.00 to comply with NYSE requirements. The split is expected to enhance marketability and attract a broader range of investors, while the company's stock will trade on a split-adjusted basis beginning March 31, 2026.

Read more →
-AGL
Feb 25, 2026
AGLGeneral
▲ +26.9%on this news· ran to +56% by day 3

agilon health Reports Fourth Quarter and Full Year Fiscal 2025 Results Issues 2026 Guidance Highlighting Expected Breakeven Adjusted EBITDA Midpoint

Agilon Health has released its fourth quarter and full year results for fiscal 2025, indicating both challenges and expectations for future improvement. The company experienced a slight revenue increase in Q4 2025, but overall annual revenue declined compared to the previous year. Significant losses were reported, with a net loss that nearly doubled year-over-year, although there is optimism regarding a possible recovery in 2026. Agilon's guidance includes expectations for breakeven Adjusted EBITDA, reflecting strategic transformation efforts underway.

Read more →

About agilon health, inc.

Westerville, OH 856 employees agilonhealth.com
Headquarters440 POLARIS PARKWAY, WESTERVILLE, OH, 43082
BIOPHARMAWATCH ELITE
Trade the next AGL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime